Moderna : Profitability moving away to 2028
>mRNA-4157 will have to wait for its phase III results - Yesterday afternoon, Moderna organised its CMD which highlighted the group's priorities and thus its financial guidance. The evolution of the product portfolio in the short term unfortunately implies a pushing back of its breakeven estimate from 2026 to 2028 (see hereafter). Starting with the positive points, we can highlight the registration filing of mRNA-1283 (new generation COVID vaccine) in the coming ...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.